The assay described in this article is based on microtitre plate technology; it employs an europium label. The streptavidin-biotin system has been used and all components are commercially available.
Introduction
. . , . ,· . . , .
better, lower detection limit as compared with imThe introduction of immunometric methods for thy-munoradiometric assays (4, 5) . Some authors now go rotropin (1, 2) led to an indirect standardisation of as far as prizing "third generation" thyrotropin assays assays for this analyte, as well as to a shortening of (6), although the lower detection limit of a method assay time and an improvement of the lower detection depends on the state of the art of analysis. limit and analytical specificity. ™ , ,, . " , The lower detection of such assays is often more The discrimination'between eu-and hyperthyroid pa-theoretical than practical, as the matrix of the zero tients became possible with this "second generation" standard has been manipulated to give a low backof assays for thyrotropin (3) . Further developments ground signal. More important, however, is the ability in assay technique have led to non-radioisotopic im-of an assay for thyrotropin to discriminate correctly munometric assays that have a comparable, if not between eu-and hyperthyroid patients in terms of defined reference ranges (6, 7) , and it may very well be that the methods giving the lowest thyrotropin concentration are not necessarily those giving the best clinical discrimination (6 -8) .
This brief communication describes the development and clinical evaluation of an immunometric assay for thyrotropin using a streptavidin-europium complex as label. The assay appears to show no serum matrix effects, which allows the standard curve to be set up in assay buffer. Using human thyrotropin as standard (calibrated against the WHO 2nd IRP 80/558), levels of 0.001 mU/1 thyrotropin can be distinguished from the zero standard, while it can be set up using commercially available reagents.
Materials and Methods

Materials \
Ninety-six-well microtitre plates (Maxisorp) were obtained from Nunc, Roskilde, Denmark.
Antibodies to thyrotropin were purchased from BoehringerMannheim, Mannheim, Germany. These consisted of a monoclonal antibody, which was immobilised onto the microtitre plate wells, and a polyclonal F ab fragment from sheep, which was biotinylated by the authors.
Standards for thyrotropin used for calibration purposes were obtained from the Behringwerke, Marburg a. d. L., Germany. Human thyrotropin for internal standards was purchased from Kabi (Kabi-Pharmacia, Erlangen, Germany).
Amidocaproylbiotin-N-hydroxysuccinimide was purchased from Sigma, Deisenhofen, Germany, the europium labelling reagent, from Pharmacia, Freiburg i. Br., Germany.
The Berilux TSH immunoluminometric assay (Behringwerke) was used for comparison.
The time-resolved fluorimeter (Arcus 1232) was from Wallac, Turku, Finland and the 250-sample semiautomated luminometer (Berthold LB-952 16T) from EG&G Berthold, Wildbad, Germany.
Other chemicals and buffer substances were obtained from Sigma or Merck, Darmstadt, Germany.
All reagents were made up in the laboratory, including those for the time-resolved fluorescence measurement. The assay buffer and enhancement solution were made up as listed below:
Assay buffer
Tris 0.05 mol/1, NaCl 0.15 mol/1, bovine serum albumin 5 g/1, bovine gamma globulins 0.5 g/1, diethylene triaminopentaacetate (DTPA) 80 mg/1, NaN 3 0.15 mol/l, Tween 20 01 ml/1 adjusted to pH 7.75.
Wash solution
Tris 0.05 mol/1, NaCl 0.15 mol/1, EDTA 0.01 mol/1, NaN 3 0 15 mol/1, Tween 20 0.1 ml/1, adjusted to pH 7.5.
Enhancement solution
Acetic acid 0.01 mol/1, tris-n-octyl phosphine oxide 38 mg/1, potassium phthalate 166 mg/1, theonyltrifluoroacetone 222 mg/1, Triton X-100 2 ml/1.
Methods
The coating of the microtitre plates, the preparation of the standards and the assay procedure are shown in table 1.
Tab. la. Components and assay scheme for the thyrotropin time resolved imrmmofluorirnetric assay (TRIFMA)
-Coating of the microtitre plate Each well was coated with 500 ng monoclonal antibody MAK 8 in phosphate buffer, pH 8.7, using a coating volume of 250 ui. The minimum coating time was 18 h at ambient temperature. Saturation of free binding sites was performed directly before assay using 50 mmol/1 carbonate buffer containing 10 g/1 bovine serum albumin, pH 9.6, with a minimum saturation time of 45 min and a volume of 350 μΐ/ well.
-Labelling of the liquid-phase antibody Sheep anti-human thyrotropin (F ab fragment) was labelled with amidocaproyl biotin N-hydroxysuccinimide ester at pH 9.4 for 18 h at ambient temperature. Separation of unreacted biotin was performed on a 15 χ 1 cm column of Ultrogel AcA-54 (IBF, Gif-sur-Yvette, F.) using 0.05 mol/1 Tris-HCl, pH 7.5, as eluent.
-Preparation of standards Human thyrotropin (Kabi-Pharmacia) was dissolved in a minimal amount of 0.15 mol/1 NaCl and further diluted with newborn calf serum to give a stock solution of around 3 U/l. Standards were made by diluting portions of stock solution to give standards containing 100, 10, 1, 0.1, 0.01 and 0.002 mU/1 thyrotropin in newborn calf serum. These standards were portioned and stored at under -30 °C until use. Each portion was used for one assay, with any surplus material being discarded.
-Assay scheme -100 μΐ standard, sample or control -100 μΐ biotinylated anti-thyrotropin -incubate 120 rnin at ambient temperature on shaker -wash with wash buffer (3 cycles on plate washer) -200 μΐ streptavidin-europium -incubate 30 min as above and wash (5 cycles on plate washer) -200 μΐ enhancement solution -incubate as above and measure in ARCUS 1232 (1 s/ well)
The biotinylation of the antibodies was performed using the active ester method with an N-hydroxysucciiiimide ester, as has already been described in detail for both biotin (9) and luminogens (10).
The assay used for comparison (Berilux TSH) was set up according to the manufacturer's instructions. The clinically relevant ranges established in L beck for this kit were: hyperthyroid patients < 0.1 mU/1, euthyroid patients 0.2-3.4 mU/1 and hypothyroid patients > 5 mU/1. These are not identical with those in the kit instructions, they have been established over a 36-month period in which the kit was used routinely on over 20000 samples.
Results
This assay demonstrates the .wide measuring range obtainable through low background and high specific signal (dynamic signal range). 6 counts per second. A high dose hook effect is first seen in excess of 500 mU/1, i. e. at concentrations which do not occur physiologically. Table 2 also shows the intra-and inter-assay precision, as well as a precision profile, with the latter representing the precision obtained with patient samples. The sample P2 is a single patient serum, samples Kl, K3-K8 commercial control sera. The imprecision of P2 is higher than that of Kl, reflecting a state of affairs often occurring, i. e. that the relative standard deviation (s%) is higher in native sera than in processed control sera.
The precision control data reflect the excellent precision at the "levels of clinical decision" between hyperand euthyroid patients around 0.2 mU/1 and between eu-and hypothyroid patients around 4 mU/1. TRIFMA gave results as borderline, the ILMA as euthyroid; in two cases, the TRIFMA classified patients as borderline, the ILMA as hyperthyroid; and in one case, the TRIFMA classified a patient as borderline euthyroid, the ILMA as borderline hyperthyroid.
Discussion
The continual improvement of immunoassays for proteohormones has led to a more reliable diagnosis in the clinic. The differences between radioimmunoassays and immunometric assays for thyrotropin has been documented elsewhere, as far as performance is concerned. The in-vitro differentiation between hyperand euthyroidism first became possible with the introduction of the immunoradiometric assays for thyrotropin. The reduction of assay times from several days to a couple of hours made emergency confirmation of overt hyperthyroidism or thyrotoxic crisis possible, with the results being back on the ward within two or three hours (1 -3, 7).
The assay reproducibility at low analyte levels was vastly improved by the reduction of the detection limit and by the robust assay design.
The introduction of non-radioisotopic labelling has not only removed the hazards of radionuclides, but has also led to a further improvement in assay lower detection limits and to the shelf-life of components, especially the tracer. In addition, the circle of immunoassay kit users has been increased, as no licensing of laboratories for radioisotopes is needed for the non-radioisotope labelled kits.
It is important not to forget the problems of measuring low analyte concentrations where "matrix effects" play a significant role (11) . At worst, the effects may give rise to spuriously elevated results due to non-specific binding of tracer in two-site immunometric assays (7) . The causes are many and include immunoglobulins (12, 13) , anti-mouse IgG (14) and rheumatoid factor (15) , to name but three. Vaidya & Beany (16) have investigated the sources of interference in assays using creatine kinase-MB as a model system.
From the above studies and observations it is clear why the aim must be to develop assays that are insensitive to such effects of components in the matrix (11, 16).
The assay described here appears to fulfil the criterion, at least under the conditions tested, of being matrixindependent. That the assay results are identical, independent of whether the standards are dissolved in assay buffer, foetal calf serum or human serum from a thyrotoxic patient supports the claims of the assays as being relatively free from serum matrix effects. The addition of "blocking antibodies" (MAK 33 -anti CK-MM Boehringer-Mannheim) is designed to act against so-called human-anti-rjiouse-antibodies sometimes present in patients treated for cancer with tagged monoclonal antibodies (12) . As the antibody used to coat the solid phase was of murine origin, it was not surprising to find that the non-specific binding of tracer to the solid-phase was reduced, and that no spurious results were obtained from the patient sera, although no screening for anti-mouse antibodies had been made, in contrast to other studies (14, 16) .
The excellent correlation with the commercial kit in the lower concentration range emphasizes the quality of the assay developed here. The values that lie below those of the commercial kit document the extremely low background of the europium fluorescence in the assay developed.
This short communication shows that it is still possible to develop immunoassays in hospital laboratories with comparable performance to those from commercial kits. This may not be of primary interest in the industrialised countries, but may play a major role in developing countries. The method developed here was made in conjunction with the International Council for Control of Iodine Deficiency Disorders (ICCIDD).
